Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 5Recruiting 4Active not recruiting 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 4Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Recurrence 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 29fludarabine 19Rituximab 15fludarabine phosphate 12Specimen Handling 8obinutuzumab 7Immunotherapy, Adoptive 7Lenalidomide 6Etoposide 6pirtobrutinib 5ibrutinib 5glofitamab 5axicabtagene ciloleucel 5Whole-Body Irradiation 5Mycophenolic Acid 5venetoclax 4polatuzumab vedotin 4Prednisone 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Blood Component Removal 4Biopsy 4pembrolizumab 3daratumumab 3X-Rays 3Vincristine 3Stem Cell Transplantation 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Non-Hodgkin × polatuzumab vedotin × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06040320 2026-05-27

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Washington University School of Medicine

Phase 1/2 Recruiting
12 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT04844866 2026-04-29

DALY 2-EU

Miltenyi Biomedicine GmbH

Phase 2 Recruiting
213 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT05260957 2025-12-31

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

University of Miami

Phase 2 Recruiting
22 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡